Novel Tool Compounds for Chromatin Research

Information

  • Research Project
  • 6735954
  • ApplicationId
    6735954
  • Core Project Number
    R41CA105604
  • Full Project Number
    1R41CA105604-01
  • Serial Number
    105604
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2004 - 20 years ago
  • Project End Date
    7/31/2007 - 17 years ago
  • Program Officer Name
    HEATH, ANNE K
  • Budget Start Date
    8/1/2004 - 20 years ago
  • Budget End Date
    7/31/2007 - 17 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/20/2004 - 20 years ago
Organizations

Novel Tool Compounds for Chromatin Research

DESCRIPTION (provided by applicant): A Phase 1 STTR proposal seeks to identify and develop novel compounds that target chromatin regulatory proteins. A yeast-based assay will be used to screen the National Cancer Institute Diversity Set library of small molecules. The assay consists of defined yeast mutants or reporter strains whose viability depends on one of a number of chromatin-regulatory functions. Compounds that specifically target those functions cause growth inhibition of the mutant strain but not the corresponding wild-type. There are three parts to the proposal. In Aim 1, two screens based on novel reporter strains will be carried out with the Diversity Set in order to identify new inhibitors of chromatin function. In Aim 2, a lead compound from a preliminary screen already conducted wilt be characterized in terms of its effect on histone acetyltransferase activity in vitro and in vivo. Aim 3 will be devoted to developing a panel of seven yeast and mammalian recombinant HAT enzymes that will be used to test the specific functions of the compounds derived from the screens. The proposed work will contribute to two underdeveloped areas. First it will provide new and valuable reagents for the study of chromatin regulation. With the exception of the histone deacetylase inhibitors (HDACs), drugs that target specific chromatin-related pathways and activities are not available. Second, the preliminary data presented here shows proof-of-concept for the yeast-based technology to rapidly identify chromatin regulation inhibitors. These two areas will be the main thrust of the future development of this project.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R41
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    207596
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:207596\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MILLIPORE CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    BILLERICA
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    018213405
  • Organization District
    UNITED STATES